MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Detail) $ in Thousands	1 Months Ended
	Sep. 30, 2019 USD ($)	Apr. 30, 2018 USD ($) milestone option	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accounts receivable			$ 4,522	$ 6,013
Kite Pharma, Inc. | Collaboration And License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received		$ 150,000
Development and sales-based milestone payments to be received		$ 3,000,000
Initial research term of agreement		6 years
Number of options to extend initial research term | option		2
Extended research term of agreement		1 year
Separate upfront fee		$ 10,000
Collaborative arrangement estimated reimbursable service costs for new research plan	$ 3,400
Collaborative arrangement transaction price	189,300
Revenues under agreement	150,000
Collaborative arrangement estimated reimbursable service costs	$ 39,300
Accounts receivable			600	100
Deferred revenue			$ 37,800	$ 56,500
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development - and sales-based milestone payments to be received		1,300,000
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development - and sales-based milestone payments to be received		$ 1,800,000
Maximum amount of achieved milestones to receive payment | milestone		10